Leaders in Pharmaceutical Business Intelligence (LPBI) Group

4:00PM – 9/30/2014: Platform Technologies & Novel Therapeutics @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

 

Real Time Media Conference Coverage  –  Business and Scientific Channels by: https://pharmaceuticalintelligence.com

3:30PM  –  Industry Leader interview by Bloomberg News

4:00PM – 9/30/2014: Platform Technologies & Novel Therapeutics

C0-Chaired by: 

• Christina Takke, Partner, Forbion Capital Partners

– What has changed in the technology and the environment in terms of Deals?

– Bioinformatics platform used on molecule behavior

– in the US the future potential is part of the valuation, in Europe only the present value not the future potential

– diversity

– how to structure companies

• Robin Davison, Director, Healthcare, Edison Investment Research

question to co-chair

– what impact geographic location has on decision regional, market penetration

Panelists: 

• Doug Doerfler, President & CEO, MaxCyte, Inc.

– Application technology, managing expectation of share holders, over 15 years, product companies play both sides, now platform companies and products. balancing act

– what is the best way to go?

– expertise drives all

• Elena Startseva, Head of Business Development, OCT

– Challenge: Therapeutics not the platform

• David Urech, Co-CEO & CSO Numab AG

– platform

– serendipity and lucky to start, T cell activation, safety to immunotherapy product

– proof of concept for ophthalmology product, franchise

• Oliver Middendorp, Co-CEO & CBO, Numab AG

• Philippe Calais, CEO, Isarna Therapeutics GmbH

– Partner is Roche, advanced the pipeline, with traditional investors, decision to approach the US VC markets capture more finance

– move to ophthalmology products from oncology, better economic rewards

– moving from 1st generation drugs, via Pharma partners, investors requested additional product to secure investment

• Tim Knotnerus, Director Business Development, AM-Pharma

– valuation of platform technology companies, is very hard.

– investors suggests alternative opportunities

– Big Pharma

• Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.

– Platform for drugs, feedback from the industry, license,

– product obsolescence in pharmaceutical, the real 4 is in the therapeutics not in the platform

– decision on exit, investment drives the structure

–

• Vincent Charlon, CEO, Anergis SA

– Lausanne based company, market opportunity, allergy vaccine, completed Phase II, product in Clinical stage, commercially shift in funds.

– confident to reproduce success, not as ease as should be, challenge continues

– Swiss based, originates in Hospital, if Global entry, locality matters less

• Daniel Elgar, CFO, Genkyotex SA

– success in one molecule does not imply success for the next. if Cystic Fibrosis was a success, next drug may not be a success.

– product assets have different characteristics, patient selection, failure of mechanism for compound to fail salvage from the clinical trial something.

–

#startup#biotech #CancerTherapy #pharmanews

@SachsAssociates@pharma_BI @BloombergNews @CancerNews @BiotechNews